Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes.
Delforge M, Selleslag D, Beguin Y, Triffet A, Mineur P, Theunissen K, Graux C, Trullemans F, Boulet D, Van Eygen K, Noens L, Van Steenweghen S, Lemmens J, Pierre P, D'hondt R, Ferrant A, Deeren D, Van De Velde A, Wynendaele W, André M, De Bock R, Efira A, Breems D, Deweweire A, Geldhof K, Pluymers W, Harrington A, MacDonald K, Abraham I, Ravoet C. Delforge M, et al. Among authors: van de velde a, van eygen k, van steenweghen s. Leuk Res. 2014 May;38(5):557-63. doi: 10.1016/j.leukres.2014.02.003. Epub 2014 Feb 14. Leuk Res. 2014. PMID: 24661630
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.
Noens L, van Lierde MA, De Bock R, Verhoef G, Zachée P, Berneman Z, Martiat P, Mineur P, Van Eygen K, MacDonald K, De Geest S, Albrecht T, Abraham I. Noens L, et al. Among authors: van lierde ma, van eygen k. Blood. 2009 May 28;113(22):5401-11. doi: 10.1182/blood-2008-12-196543. Epub 2009 Apr 6. Blood. 2009. PMID: 19349618 Free article.
Results from the Belgian mantle cell lymphoma registry.
Vergote V, Janssens A, André M, Bonnet C, Van Hende V, Van Den Neste E, Van Eygen K, Maerevoet M, Pranger D, Schroyens W, Debussche S, Maertens V, Beel K, Lemmens J, Caron C, Delrieu V, Van Den Broeck I, Vanstraelen G, Jacquy C, Schauvlieghe L, De Samblanx H, Madoe V, Meers S, Boulet D, Verhoef G, Van Hoof A. Vergote V, et al. Among authors: van hende v, van hoof a, van eygen k, van den neste e, van den broeck i. Acta Clin Belg. 2017 Jun;72(3):172-178. doi: 10.1080/17843286.2017.1293328. Epub 2017 Feb 22. Acta Clin Belg. 2017. PMID: 28222652 Free article.
Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.
Houot R, Cartron G, Bijou F, de Guibert S, Salles GA, Fruchart C, Bouabdallah K, Maerevoet M, Feugier P, Le Gouill S, Tilly H, Casasnovas RO, Moluçon-Chabrot C, Van Den Neste E, Zachee P, Andre M, Bonnet C, Haioun C, Van Hoof A, Van Eygen K, Molina L, Nicolas-Virelizier E, Ruminy P, Morschhauser F. Houot R, et al. Among authors: van hoof a, van eygen k, van den neste e. Leukemia. 2019 Mar;33(3):776-780. doi: 10.1038/s41375-018-0282-y. Epub 2018 Oct 5. Leukemia. 2019. PMID: 30291335 Free article. Clinical Trial. No abstract available.
Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium.
Devos T, Verhoef G, Steel E, Mazure D, Lewalle P, Bron D, Berneman Z, Benghiat FS, Mineur P, Theunissen K, Zachée P, Doyen C, Put N, Lejeune M, Van Eygen K, Havelange V, Reusens M, Pluymers W, Peeters K. Devos T, et al. Among authors: van eygen k. Acta Haematol. 2019;142(4):197-207. doi: 10.1159/000499329. Epub 2019 Jun 4. Acta Haematol. 2019. PMID: 31163431 Free article. Clinical Trial.
Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes.
Garcia-Manero G, Diez-Campelo M, Vellenga E, Jacoby MA, Merchan B, Breems D, Cortelezzi A, Doronin V, Gomez V, Beckers M, Della Porta MG, Varsos H, Xiu L, DeAngelis N, Nnane I, Rose E, van Eygen K. Garcia-Manero G, et al. Among authors: van eygen k. Am J Hematol. 2021 Apr 1;96(4):E111-E114. doi: 10.1002/ajh.26095. Epub 2021 Jan 31. Am J Hematol. 2021. PMID: 33448430 Free article. Clinical Trial. No abstract available.
Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
Devos T, Havelange V, Theunissen K, Meers S, Benghiat FS, Gadisseur A, Vanstraelen G, Vellemans H, Bailly B, Granacher N, Lewalle P, De Becker A, Van Eygen K, Janssen M, Triffet A, Vrelust I, Deeren D, Mazure D, Bekaert J, Beck M, Selleslag D. Devos T, et al. Among authors: van eygen k. Ann Hematol. 2021 Jul;100(7):1723-1732. doi: 10.1007/s00277-021-04507-x. Epub 2021 May 4. Ann Hematol. 2021. PMID: 33942128 Free PMC article.
Real-life data of luspatercept in lower-risk myelodysplastic syndromes advocate new research objectives.
Heyrman B, Meers S, Sid S, Put N, Theunissen K, Van Eygen K, De Beule N, Clauwaert M, Maes H, Salembier A, Lemmens J, Velde AV, Selleslag D, Bouziotis J, De Becker A, Anguille S. Heyrman B, et al. Among authors: van eygen k. EJHaem. 2024 Oct 4;5(5):1096-1099. doi: 10.1002/jha2.1027. eCollection 2024 Oct. EJHaem. 2024. PMID: 39415916 Free PMC article. No abstract available.
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study.
Steensma DP, Fenaux P, Van Eygen K, Raza A, Santini V, Germing U, Font P, Diez-Campelo M, Thepot S, Vellenga E, Patnaik MM, Jang JH, Varsos H, Bussolari J, Rose E, Sherman L, Sun L, Wan Y, Dougherty S, Huang F, Feller F, Rizo A, Platzbecker U. Steensma DP, et al. Among authors: van eygen k. J Clin Oncol. 2021 Jan 1;39(1):48-56. doi: 10.1200/JCO.20.01895. Epub 2020 Oct 27. J Clin Oncol. 2021. PMID: 33108243 Clinical Trial.
54 results